CellWell record HH-365673
Sulforaphane as a Therapeutic Target for Sarcopenia in Type 2 Diabetes: Mechanistic Insights and Translational Evidence
Ayanda Ngcobo; Samukelisiwe C. Shabalala; Nokulunga Hlengwa; Ndivhuwo Muvhulawa; Patrick Orlando; Sonia Silvestri; Luca Tiano; Phiwayinkosi Vusi Dludla
Antioxidants ยท 2026
In plain language
Preclinical evidence indicates sulforaphane preserves skeletal muscle in type 2 diabetes through Nrf2 activation, though limited clinical evidence supports muscle protection.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-365673
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.